Literature DB >> 18763195

The improvement in quality of life after breast reduction is comparable to that after major joint replacement.

Kai M Saariniemi1, Harri Sintonen, Hannu O Kuokkanen.   

Abstract

The loss of health-related quality of life (QoL) associated with symptomatic breast hypertrophy has been well documented. Measuring QoL with a generic, single index, instrument enables comparisons between different diseases, conditions, and specialities. The aim of this study was to measure the health-related QoL of patients before and after reduction mammaplasty, and to compare it to that of the age-standardised female population, and patients treated by total joint replacement. Health-related QoL was measured using the 15D score from 82 patients at baseline, and at six months after breast reduction surgery from 29 patients who had been randomised to the procedure. At baseline those who had had reduction mammaplasty had significantly lower health-related QoL than the age-standardised female population, but by six months it had improved to the same level with population. The preoperative health deficit of symptomatic breast hypertrophy was equal to that of symptomatic major joint arthrosis. The effect of intervention of reduction mammaplasty was comparable to that of hip and more than knee total joint replacement.

Entities:  

Mesh:

Year:  2008        PMID: 18763195     DOI: 10.1080/02844310802098433

Source DB:  PubMed          Journal:  Scand J Plast Reconstr Surg Hand Surg        ISSN: 0284-4311


  2 in total

1.  Treatment of symptomatic macromastia in a breast unit.

Authors:  Fernando Hernanz; Rosa Santos; Arantxa Arruabarrena; José Schneider; Manuel Gómez Fleitas
Journal:  World J Surg Oncol       Date:  2010-11-01       Impact factor: 2.754

2.  Self-reported psychological development in cosmetic breast surgery patients.

Authors:  María Ángeles Pérez-San-Gregorio; Agustín Martín-Rodríguez; María Jesús Arias-Moreno; María Esther Rincón-Fernández; José Ignacio Ortega-Martínez
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.